Bio-Rad Laboratories (BIO) versus Quanterix (QTRX) Critical Survey

Quanterix (NASDAQ: QTRX) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of current ratings and recommmendations for Quanterix and Bio-Rad Laboratories, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix 0 0 4 0 3.00
Bio-Rad Laboratories 0 1 4 0 2.80

Quanterix presently has a consensus target price of $26.50, suggesting a potential upside of 59.25%. Bio-Rad Laboratories has a consensus target price of $298.75, suggesting a potential upside of 20.72%. Given Quanterix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Quanterix is more favorable than Bio-Rad Laboratories.

Insider and Institutional Ownership

42.4% of Quanterix shares are owned by institutional investors. Comparatively, 64.5% of Bio-Rad Laboratories shares are owned by institutional investors. 28.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Quanterix and Bio-Rad Laboratories’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quanterix $22.87 million 15.96 -$27.01 million ($8.30) -2.00
Bio-Rad Laboratories $2.16 billion 3.41 $114.74 million $4.10 60.36

Bio-Rad Laboratories has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quanterix and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quanterix N/A N/A N/A
Bio-Rad Laboratories 5.31% 3.63% 2.48%

Summary

Bio-Rad Laboratories beats Quanterix on 9 of the 12 factors compared between the two stocks.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company's products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reviewing SSAB Svenskt Stal  and Haynes International
Reviewing SSAB Svenskt Stal and Haynes International
Head-To-Head Comparison: Minerals Technologies  & Luxfer
Head-To-Head Comparison: Minerals Technologies & Luxfer
Enova International  versus Credit Acceptance  Head to Head Contrast
Enova International versus Credit Acceptance Head to Head Contrast
Critical Analysis: Yandex  and Its Competitors
Critical Analysis: Yandex and Its Competitors
ClearPoll Market Cap Achieves $8.14 Million
ClearPoll Market Cap Achieves $8.14 Million
CRTCoin  Price Hits $0.40 on Top Exchanges
CRTCoin Price Hits $0.40 on Top Exchanges


© 2006-2018 Ticker Report. Google+.